相关实验视频

Updated: Jun 28, 2025

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

CD58 变化通过诱导 PDL1 和 IDO 在扩散大B细胞淋巴瘤中来控制抗瘤免疫反应

Xiyue Xu¹, Yidan Zhang¹, Yaxiao Lu¹

¹National Key Laboratory of Druggability Evaluation and Systematic Translational Medicine and Department of Lymphoma, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, the Sino-US Center for Lymphoma and Leukemia Research, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.

Cancer research

|April 18, 2024

概括

在扩散性大B细胞淋巴瘤 (DLBCL) 中,CD58的损失会损害抗瘤免疫力和R-CHOP治疗反应. 恢复CD58功能可以克服在DLBCL中对CAR T细胞治疗的免疫逃避和抵抗.

科学领域:

免疫学免疫学免疫学
在瘤学瘤学.
遗传学是一个遗传学.

背景情况:

免疫监测基因中经常出现的遗传异常会影响扩散型大B细胞淋巴瘤 (DLBCL) 的进展和治疗反应.
CD58是一种与免疫细胞上的CD2相互作用的分子,在DLBCL中经常发生变化,这表明它在抗瘤免疫中起作用.

研究的目的:

在DLBCL中全面分析CD58的基因组特征.
研究CD58变化的功能后果对免疫逃避和治疗耐药性的研究.
探索针对DLBCL中CD58的治疗策略.

主要方法:

使用了针对下一代测序,RNA测序 (RNA-seq),全外因子测序和单细胞RNA-seq.
基因组变化和CD58表达水平与治疗反应和患者存活率相关.
通过分子通路分析阐明了CD58介导免疫调节的机制.

主要成果:

在DLBCL中,CD58的变异 (9.1%的突变,44.7%的拷贝数丢失) 是常见的.
CD58基因变异和低表达与对R-CHOP治疗反应不佳和生存结果差异相关.
通过通过LYN/CD22/SHP1通路调节PDL1和IDO,CD58缺乏促进了对CAR T细胞治疗的免疫逃避和抵抗.

结论:

在DLBCL中CD58的损失有助于免疫逃避和治疗抵抗.
针对CD58介导通路,包括PDL1和IDO,为DLBCL提供了潜在的治疗策略.
涉及CD58激活与免疫检查点抑制剂或IDO抑制剂的组合疗法可能会使DLBCL对CAR T细胞治疗敏感.

更多相关视频

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Published on: June 12, 2021

Enhancing Tumor Content through Tumor Macrodissection

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

相关概念视频

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...

T Cell Activation and Clonal Selection

T Cell Activation and Clonal Selection

T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.